Preliminary results of the Multicenter Observational Study with Enoximone in Cardiac surgery (MOSEC).

•Nowadays, patients undergoing cardiac surgery are increasingly older and present to surgery with multiple risk factors.•In these settings, cardio-pulmonary bypass may increase postoperative morbidity and mortality.•Indeed, the well-known systemic inflammatory response following on-pump cardiac surgery, with its possible sequelae, may play a role in determining postoperative outcomes•In the last decades many efforts have been made to avoid cardio-pulmonary bypass or at least mitigate its detrimental effects•Enoximone modulates hemodynamics and phlogosis; hence exherting postoperative effects on organ function, and endothelial integrity•Consistently, our results confirm postoperative outcomes amelioration among cardiac surgery patients receiving Enoximone.